Bristol-Myers Squibb (BMY) Tops Q4 EPS by 10c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. SBUX
9. AXP
10. ZETA

Go back to Bristol-Myers Squibb (BMY) Tops Q4 EPS by 10c

CheckMate -141, a Pivotal Phase 3 Opdivo (nivolumab) Head and Neck Cancer Trial, Stopped Early

January 28, 2016 6:59 AM EST

Opdivo Study Demonstrates Superior Overall Survival Compared to Therapy of Investigators Choice in Patients with Recurrent or Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) today announced that a randomized Phase 3 study evaluating Opdivo (nivolumab) versus investigators choice in patients with... More